- Supported exchanges /
- AU /
- CU6.AU
Clarity Pharmaceuticals Ltd (CU6 AU) stock market data APIs
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development and clinical stage radiopharmaceuticals products in Australia and the United States. The company's products include SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2; developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. It develops theranostic therapy and imaging products for the treatment of cancer in children and adults. The company was incorporated in 2010 and is based in Sydney, Australia.
Clarity Pharmaceuticals Ltd Financial Data Overview
7.7 | |
7.67 | |
- | |
7.77 | |
7.41 | |
0.975-7.95 | |
2 446 M | |
316 M | |
11 507 K | |
-0.04 | |
1.572 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Clarity Pharmaceuticals Ltd Fundamental Data is available in our Financial Data APIs
- Net Revenue 11 507 K
- EBITDA -44 647 592
- Earnings Per Share -0.16
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Clarity Pharmaceuticals Ltd Earnings via APIs
- Latest Release 2023-02-28
- EPS/Forecast -0.03
Get Clarity Pharmaceuticals Ltd End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: